Insights into obstructive sleep apnea research

Sleep Medicine

Volumn 15, Issue 5, 2014, Pages 485-495

  Badran, Mohammad ^a   Ayas, Najib ^b   Laher, Ismail ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Animal models; Endothelium; Inflammation; Intermittent hypoxia; Obesity; Oxidative stress

Indexed keywords

C REACTIVE PROTEIN; REACTIVE OXYGEN METABOLITE;

AIRWAY OBSTRUCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MODEL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; INTERMITTENT HYPOXIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; MEDICAL RESEARCH; STROKE;

ANIMALS; BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; HYPERTENSION; OBESITY; OXIDATIVE STRESS; SLEEP APNEA, OBSTRUCTIVE; STROKE;

EID: 84900028281     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2014.01.009     Document Type: Review

References (175)

1. Golbidi S., Badran M., Ayas N., Laher I. Cardiovascular consequences of sleep apnea. Lung 2012, 190:113-132.
2. Gleeson K., Zwillich C.W., White D.P. The influence of increasing ventilatory effort on arousal from sleep. Am Rev Respir Dis 1990, 142:295-300.
3. Peppard P.E., Young T., Barnet J.H., Palta M., Hagen E.W., Hla K.M. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013, 177:1006-1014.
4. Bixler E.O., Vgontzas A.N., Lin H.M., Ten Have T., Rein J., Vela-Bueno A., et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001, 163:608-613.
5. Duran J., Esnaola S., Rubio R., Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med 2001, 163:685-689.
6. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230-1235.
7. Punjabi N.M. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008, 5:136-143.
8. Netzer N.C., Stoohs R.A., Netzer C.M., Clark K., Strohl K.P. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999, 131:485-491.
9. Practice parameters for the indications for polysomnography and related procedures. Polysomnography Task Force, American Sleep Disorders Association Standards of Practice Committee. Sleep 1997, 20:406-422.
10. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999, 22:667-689.
11. AlGhanim N., Comondore V.R., Fleetham J., Marra C.A., Ayas N.T. The economic impact of obstructive sleep apnea. Lung 2008, 186:7-12.
12. Shamsuzzaman A.S., Gersh B.J., Somers V.K. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003, 290:1906-1914.
13. Kapur V.K. Obstructive sleep apnea: diagnosis, epidemiology, and economics. Respir Care 2010, 55:1155-1167.
14. Fletcher E.C., DeBehnke R.D., Lovoi M.S., Gorin A.B. Undiagnosed sleep apnea in patients with essential hypertension. Ann Intern Med 1985, 103:190-195.
15. Silverberg D.S., Oksenberg A., Iaina A. Sleep-related breathing disorders as a major cause of essential hypertension: fact or fiction?. Curr Opin Nephrol Hypertens 1998, 7:353-357.
16. Lavie P., Herer P., Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ. 2000, 320:479-482.
17. Pedrosa R.P., Drager L.F., Gonzaga C.C., Sousa M.G., de Paula L.K., Amaro A.C., et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011, 58:811-817.
18. Peppard P.E., Young T., Palta M., Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378-1384.
19. Peppard P.E. Is obstructive sleep apnea a risk factor for hypertension? - Differences between the Wisconsin Sleep Cohort and the Sleep Heart Health Study. J Clin Sleep Med 2009, 5:404-405.
20. Phillips C.L., O'Driscoll D.M. Hypertension and obstructive sleep apnea. Nat Sci Sleep 2013, 5:43-52.
21. Allahdadi K.J., Walker B.R., Kanagy N.L. Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension 2005, 45:705-709.
22. Dematteis M., Julien C., Guillermet C., Sturm N., Lantuejoul S., Mallaret M., et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008, 177:227-235.
23. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
24. Aronsohn R.S., Whitmore H., Van Cauter E., Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 2010, 181:507-513.
25. Einhorn D., Stewart D.A., Erman M.K., Gordon N., Philis-Tsimikas A., Casal E. Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus. Endocr Pract 2007, 13:355-362.
26. Foster G.D., Sanders M.H., Millman R., Zammit G., Borradaile K.E., Newman A.B., et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 2009, 32:1017-1019.
27. Laaban J.P., Daenen S., Léger D., Pascal S., Bayon V., Slama G., et al. Prevalence and predictive factors of sleep apnoea syndrome in type 2 diabetic patients. Diabetes Metab 2009, 35:372-377.
28. Resnick H.E., Redline S., Shahar E., Gilpin A., Newman A., Walter R., et al. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care 2003, 26:702-709.
29. Pamidi S., Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link?. Front Neurol 2012, 3:126.
30. Botros N., Concato J., Mohsenin V., Selim B., Doctor K., Yaggi H.K. Obstructive sleep apnea as a risk factor for type 2 diabetes. Am J Med 2009, 122:1122-1127.
31. Konecny T., Kuniyoshi F.H., Orban M., Pressman G.S., Kara T., Gami A., et al. Under-diagnosis of sleep apnea in patients after acute myocardial infarction. J Am Coll Cardiol 2010, 56:742-743.
32. Mooe T., Franklin K.A., Holmstrom K., Rabben T., Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med 2001, 164:1910-1913.
33. Shah N.A., Yaggi H.K., Concato J., Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. Sleep Breath 2010, 14:131-136.
34. Sorajja D., Gami A.S., Somers V.K., Behrenbeck T.R., Garcia-Touchard A., Lopez-Jimenez F. Independent association between obstructive sleep apnea and subclinical coronary artery disease. Chest 2008, 133:927-933.
35. Gami A.S., Rader S., Svatikova A., Wolk R., Herold D.L., Huyber C., et al. Familial premature coronary artery disease mortality and obstructive sleep apnea. Chest 2007, 131:118-121.
36. Peker Y., Hedner J., Kraiczi H., Loth S. Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med 2000, 162:81-86.
37. Drager L.F., Polotsky V.Y., Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest 2011, 140:534-542.
38. Yumino D., Tsurumi Y., Takagi A., Suzuki K., Kasanuki H. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol 2007, 99:26-30.
39. Shah N., Redline S., Yaggi H.K., Wu R., Zhao C.G., Ostfeld R., et al. Obstructive sleep apnea and acute myocardial infarction severity: ischemic preconditioning?. Sleep Breath 2013, 17:819-826.
40. Shahar E., Whitney C.W., Redline S., Lee E.T., Newman A.B., Nieto F.J., et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001, 163:19-25.
41. Yaggi H.K., Concato J., Kernan W.N., Lichtman J.H., Brass L.M., Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005, 353:2034-2041.
42. Redline S., Yenokyan G., Gottlieb D.J., Shahar E., O'Connor G.T., Resnick H.E., et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med 2010, 182:269-277.
43. Arzt M., Young T., Finn L., Skatrud J.B., Bradley T.D. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 2005, 172:1447-1451.
44. Morgan B.J., Reichmuth K.J., Peppard P.E., Finn L., Barczi S.R., Young T., et al. Effects of sleep-disordered breathing on cerebrovascular regulation: a population-based study. Am J Respir Crit Care Med 2010, 182:1445-1452.
45. Sin D.D., Fitzgerald F., Parker J.D., Newton G., Floras J.S., Bradley T.D. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999, 160:1101-1106.
46. Gottlieb D.J., Yenokyan G., Newman A.B., O'Connor G.T., Punjabi N.M., Quan S.F., et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010, 122:352-360.
47. Chan J., Sanderson J., Chan W., et al. Prevalence of sleep-disordered breathing in diastolic heart failure. Chest 1997, 111:1488-1493.
48. Damy T., Margarit L., Noroc A., Bodez D., Guendouz S., Boyer L., et al. Prognostic impact of sleep-disordered breathing and its treatment with nocturnal ventilation for chronic heart failure. Eur J Heart Fail 2012, 14:1009-1019.
49. MacDonald M., Fang J., Pittman S.D., White D.P., Malhotra A. The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers. J Clin Sleep Med 2008, 4:38-42.
50. Oldenburg O., Lamp B., Faber L., Teschler H., Horstkotte D., Topfer V. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail 2007, 9:251-257.
51. Marin J.M., Carrizo S.J., Vicente E., Agusti A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005, 365:1046-1053.
52. Kelly T., Yang W., Chen C.S., Reynolds K., He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008, 32:1431-1437.
53. Fakhouri T.H., Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of obesity among older adults in the United States, 2007-2010. NCHS Data Brief 2012, 1-8.
54. Finkelstein E.A., Brown D.S., Wrage L.A., Allaire B.T., Hoerger T.J. Individual and aggregate years-of-life-lost associated with overweight and obesity. Obesity (Silver Spring) 2010, 18:333-339.
55. Young T., Peppard P.E., Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002, 165:1217-1239.
56. Loube D.I., Loube A.A., Mitler M.M. Weight loss for obstructive sleep apnea: the optimal therapy for obese patients. J Am Diet Assoc 1994, 94:1291-1295.
57. Pillar G., Shehadeh N. Abdominal fat and sleep apnea: the chicken or the egg?. Diabetes Care 2008, 31(Suppl. 2):S303-S309.
58. Wolk R., Shamsuzzaman A.S., Somers V.K. Obesity, sleep apnea, and hypertension. Hypertension 2003, 42:1067-1074.
59. Schwartz A.R., Patil S.P., Squier S., Schneider H., Kirkness J.P., Smith P.L. Obesity and upper airway control during sleep. J Appl Physiol 1985, 2010(108):430-435.
60. Horner R.L., Mohiaddin R.H., Lowell D.G., Shea S.A., Burman E.D., Longmore D.B., et al. Sites and sizes of fat deposits around the pharynx in obese patients with obstructive sleep apnoea and weight matched controls. Eur Respir J 1989, 2:613-622.
61. Kopelman P.G. Obesity as a medical problem. Nature 2000, 404:635-643.
62. Vincent H.K., Taylor A.G. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006, 30:400-418.
63. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
64. Keaney J.F.J., Larson M.G., Vasan R.S., Wilson P.W., Lipinska I., Corey D., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003, 23:434-439.
65. Hosogai N., Fukuhara A., Oshima K., Mivata Y., Tanaka S., Segawa K., et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901-911.
66. Alam I., Lewis K., Stephens J.W., Baxter J.N. Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. Obes Rev 2007, 8:119-127.
67. Phillips B.G., Kato M., Narkiewicz K., Choe I., Somers V.K. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000, 279:H234-H237.
68. Tokuda F., Sando Y., Matsui H., Koike H., Yokoyama T. Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. Intern Med 2008, 47:1843-1849.
69. Sharma S.K., Kumpawat S., Goel A., Banga A., Ramakrishnan L., Chaturvedi P. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 2007, 8:12-17.
70. Ursavas A., Ilcol Y.O., Nalci N., Karadag M., Ege E. Ghrelin, leptin, adiponectin, and resistin levels in sleep apnea syndrome: role of obesity. Ann Thorac Med 2010, 5:161-165.
71. Cherneva R.V., Georgiev O.B., Petrova D.S., Mondeshki T.L., Ruseva S.R., Cakova A.D., et al. Resistin - the link between adipose tissue dysfunction and insulin resistance in patients with obstructive sleep apnea. J Diabetes Metab Disord 2013, 12:5.
72. Vatansever E., Surmen-Gur E., Ursavas A., Karadag M. Obstructive sleep apnea causes oxidative damage to plasma lipids and proteins and decreases adiponectin levels. Sleep Breath 2011, 15:275-282.
73. Zhang X.L., Yin K.S., Wang H., Su S. Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration 2006, 73:73-77.
74. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
75. Duranteau J., Chandel N.S., Kulisz A., Shao Z., Schumacker P.T. Intracellular signaling by reactive oxygen species during hypoxia in cardiomyocytes. J Biol Chem 1998, 273:11619-11624.
76. Babior B.M. Phagocytes and oxidative stress. Am J Med 2000, 109:33-44.
77. Mohazzab K.M., Kaminski P.M., Wolin M.S. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994, 266:H2568-H2572.
78. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
79. Schulz R., Mahmoudi S., Hattar K., Sibelius U., Olschewski H., Mayer K., et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000, 162:566-570.
80. Dyugovskaya L., Lavie P., Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002, 165:934-939.
81. Dyugovskaya L., Polyakov A., Lavie P., Lavie L. Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med 2008, 177:544-554.
82. Troncoso Brindeiro C.M., da Silva A.Q., Allahdadi K.J., Youngblood V., Kanagy N.L. Reactive oxygen species contribute to sleep apnea-induced hypertension in rats. Am J Physiol Heart Circ Physiol 2007, 293:H2971-H2976.
83. Nisbet R.E., Graves A.S., Kleinhenz D.J., Rupnow H.L., Reed A.L., Fan T.H., et al. The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. Am J Respir Cell Mol Biol 2009, 40:601-609.
84. Jun J., Savransky V., Nanayakkara A., Bevans S., Li J., Smith P.L., et al. Intermittent hypoxia has organ-specific effects on oxidative stress. Am J Physiol Regul Integr Comp Physiol 2008, 295:R1274-R1281.
85. Peng Y.J., Nanduri J., Yuan G., Wang N., Deneris E., Pendyala S., et al. NADPH oxidase is required for the sensory plasticity of the carotid body by chronic intermittent hypoxia. J Neurosci 2009, 29:4903-4910.
86. Lavie L., Vishnevsky A., Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004, 27:123-128.
87. Barcelo A., Miralles C., Barbe F., Vila M., Pons S., Agusti A.G. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000, 16:644-647.
88. Kizawa T., Nakamura Y., Takahashi S., Sakurai S., Yamauchi K., Inoue H. Pathogenic role of angiotensin II and oxidised LDL in obstructive sleep apnoea. Eur Respir J 2009, 34:1390-1398.
89. Yamauchi M., Nakano H., Maekawa J., Okamoto Y., Ohnishi Y., Suzuki T., et al. Oxidative stress in obstructive sleep apnea. Chest 2005, 127:1674-1679.
90. Liu J.N., Zhang J.X., Lu G., Qiu Y., Yang D., Yin G.Y., et al. The effect of oxidative stress in myocardial cell injury in mice exposed to chronic intermittent hypoxia. Chin Med J (Engl) 2010, 123:74-78.
91. Savransky V., Bevans S., Nanaykkara A., Li J., Smith P.L., Torbenson M.S., et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007, 293:G871-G877.
92. Rosa D.P., Martinez D., Picada J.N., Semedo J.G., Marroni N.P. Hepatic oxidative stress in an animal model of sleep apnoea: effects of different duration of exposure. Comp Hepatol 2011, 10:1.
93. Xu W., Chi L., Xu R., et al. Increased production of reactive oxygen species contributes to motor neuron death in a compression mouse model of spinal cord injury. Spinal Cord 2005, 43:204-213.
94. Christou K., Moulas A.N., Pastaka C., Gourgoulianis K.I. Antioxidant capacity in obstructive sleep apnea patients. Sleep Med 2003, 4:225-228.
95. Barcelo A., Barbe F., de la Pena M., Vila M., Perez G., Pierola J., et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006, 27:756-760.
96. Katsoulis K., Kontakiotis T., Spanogiannis D., Vlachogiannis E., Kougioulis M., Gerou S., et al. Total antioxidant status in patients with obstructive sleep apnea without comorbidities: the role of the severity of the disease. Sleep Breath 2011, 15:861-866.
97. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
98. McNicholas W.T. Obstructive sleep apnea and inflammation. Prog Cardiovasc Dis 2009, 51:392-399.
99. Valen G., Yan Z.Q., Hansson G.K. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001, 38:307-314.
100. Yamauchi M., Tamaki S., Tomoda K., Yoshikawa M., Fukuoka A., Makinodan K., et al. Evidence for activation of nuclear factor kappaB in obstructive sleep apnea. Sleep Breath 2006, 10:189-193.
101. Htoo A.K., Greenberg H., Tongia S., Chen G., Henderson T., Wilson D., et al. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 2006, 10:43-50.
102. von der Thusen J.H., Kuiper J., van Berkel T.J., Biessen E.A. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003, 55:133-166.
103. Haddad J.J. Pharmaco-redox regulation of cytokine-related pathways: from receptor signaling to pharmacogenomics. Free Radic Biol Med 2002, 33:907-926.
104. Constantinidis J., Ereliadis S., Angouridakis N., Konstantinidis I., Vital V., Angouridaki C. Cytokine changes after surgical treatment of obstructive sleep apnoea syndrome. Eur Arch Otorhinolaryngol 2008, 265:1275-1279.
105. Dyugovskaya L., Lavie P., Hirsh M., Lavie L. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 2005, 25:820-828.
106. Dyugovskaya L., Lavie P., Lavie L. Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med 2003, 168:242-249.
107. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Hopper K., Lotsikas A., Lin H.M., et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000, 85:1151-1158.
108. Minoguchi K., Yokoe T., Tazaki T., Minoguchi H., Tanaka A., Oda N., et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005, 172:625-630.
109. Ohga E., Tomita T., Wada H., Yamamoto H., Nagase T., Ouchi Y. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 1985, 2003(94):179-184.
110. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000, 101:2149-2153.
111. Yokoe T., Minoguchi K., Matsuo H., Oda N., Minoguchi H., Yoshino G., et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003, 107:1129-1134.
112. Libby P., Willerson J.T., Braunwald E. C-reactive protein and coronary heart disease. N Engl J Med 2004, 351:295-298. author reply 295-8.
113. Willerson J.T., Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004, 109:II2-II10.
114. Kobayashi S., Inoue N., Ohashi Y., Terashima M., Matsui K., Mori T., et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003, 23:1398-1404.
115. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
116. Shamsuzzaman A.S., Winnicki M., Lanfranchi P., Wolk R., Kara T., Accurso V., et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002, 105:2462-2464.
117. Guven S.F., Turkkani M.H., Ciftci B., Ciftci T.U., Erdogan Y. The relationship between high-sensitivity C-reactive protein levels and the severity of obstructive sleep apnea. Sleep Breath 2012, 16:217-221.
118. Guilleminault C., Kirisoglu C., Ohayon M.M. C-reactive protein and sleep-disordered breathing. Sleep 2004, 27:1507-1511.
119. Saletu M., Nosiska D., Kapfhammer G., Lalouschek W., Saletu B., Benesch T., et al. Structural and serum surrogate markers of cerebrovascular disease in obstructive sleep apnea (OSA): association of mild OSA with early atherosclerosis. J Neurol 2006, 253:746-752.
120. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
121. Dyugovskaya L., Lavie P., Lavie L. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann N Y Acad Sci 2005, 1051:340-350.
122. Bokinsky G., Miller M., Ault K., Husband P., Mitchell J. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest 1995, 108:625-630.
123. Geiser T., Buck F., Meyer B.J., Bassetti C., Haeberli A., Gugger M. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002, 69:229-234.
124. Lavie L. Oxidative stress inflammation and endothelial dysfunction in obstructive sleep apnea. Front Biosci (Elite Ed) 2012, 4:1391-1403.
125. Gavins F., Yilmaz G., Granger D.N. The evolving paradigm for blood cell-endothelial cell interactions in the cerebral microcirculation. Microcirculation 2007, 14:667-681.
126. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
127. Ursavas A., Karadag M., Rodoplu E., Yilmaztepe A., Oral H.B., Gozu R.O. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration 2007, 74:525-532.
128. Jelic S., Le Jemtel T.H. Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea. Trends Cardiovasc Med 2008, 18:253-260.
129. Kato M., Roberts-Thomson P., Phillips B.G., Havens W.G., Winnicki M., Accurso V., et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000, 102:2607-2610.
130. Ip M.S., Lam B., Chan L.Y., Zheng L., Tsang K.W., Fung P.C., et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000, 162:2166-2171.
131. Teramoto S., Kume H., Matsuse T., Ishii T., Miyashita A., Akishita M., et al. Oxygen administration improves the serum level of nitric oxide metabolites in patients with obstructive sleep apnea syndrome. Sleep Med 2003, 4:403-407.
132. Schulz R., Seeger W., Grimminger F. Serum nitrite/nitrate levels in obstructive sleep apnea. Am J Respir Crit Care Med 2001, 164:1997-1998.
133. Svatikova A., Wolk R., Wang H.H., Otto M.E., Bybee K.A., Singh R.J., et al. Circulating free nitrotyrosine in obstructive sleep apnea. Am J Physiol Regul Integr Comp Physiol 2004, 287:R284-R287.
134. Tabrizi-Fard M.A., Maurer T.S., Fung H.L. In vivo disposition of 3-nitro-L-tyrosine in rats: implications on tracking systemic peroxynitrite exposure. Drug Metab Dispos 1999, 27:429-431.
135. Yung L.M., Leung F.P., Yao X., Chen Z.Y., Huang Y. Reactive oxygen species in vascular wall. Cardiovasc Hematol Disord Drug Targets 2006, 6:1-19.
136. Antoniades C., Shirodaria C., Warrik N., Cai S., de Bono J., Lee J., et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114:1193-1201.
137. Ohike Y., Kozaki K., Iijima K., Eto M., Kojima T., Ohga E., et al. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure-possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J 2005, 69:221-226.
138. Tanaka T., Nakamura H., Yodoi J., Bloom E.T. Redox regulation of the signaling pathways leading to eNOS phosphorylation. Free Radic Biol Med 2005, 38:1231-1242.
139. Hendricks J.C., Kline L.R., Kovalski R.J., O'Brien J.A., Morrison A.R., Pack A.I. The English bulldog: a natural model of sleep-disordered breathing. J Appl Physiol 1985, 1987(63):1344-1350.
140. Veasey S.C., Chachkes J., Fenik P., Hendricks J.C. The effects of ondansetron on sleep-disordered breathing in the English bulldog. Sleep 2001, 24:155-160.
141. Veasey S.C., Fenik P., Panckeri K., Pack A.I., Hendricks J.C. The effects of trazodone with L-tryptophan on sleep-disordered breathing in the English bulldog. Am J Respir Crit Care Med 1999, 160:1659-1667.
142. Carley D.W., Olopade C., Ruigt G.S., Radulovacki M. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 2007, 30:35-41.
143. van Lunteren E. Effects of genetic obesity on rat upper airway muscle and diaphragm contractile properties. Eur Respir J 1996, 9:2139-2144.
144. Alonso-Galicia M., Brands M.W., Zappe D.H., Hall J.E. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 1996, 28:1047-1054.
145. Fredersdorf S., Thumann C., Ulucan C., Griese D.P., Luchner A., Riegger G.A., et al. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 2004, 13:11-19.
146. Lee S.D., Nakano H., Farkas G.A. Adenosinergic modulation of ventilation in obese zucker rats. Obes Res 2005, 13:545-555.
147. Radulovacki M., Trbovic S., Carley D.W. Hypotension reduces sleep apneas in Zucker lean and Zucker obese rats. Sleep 1996, 19:767-773.
148. Peters L.L., Robledo R.F., Bult C.J., Churchill G.A., Paigen B.J., Svenson K.L. The mouse as a model for human biology: a resource guide for complex trait analysis. Nat Rev Genet 2007, 8:58-69.
149. Berry-Kravis E.M., Zhou L., Rand C.M., Weese-Mayer D.E. Congenital central hypoventilation syndrome: PHOX2B mutations and phenotype. Am J Respir Crit Care Med 2006, 174:1139-1144.
150. 2 sensitivity. J Auton Nerv Syst 1997, 63:137-143.
151. Brennick M.J., Kuna S.T., Pickup S., Cater J., Schwab R.J. Respiratory modulation of the pharyngeal airway in lean and obese mice. Respir Physiol Neurobiol 2011, 175:296-302.
152. Brennick M.J., Pack A.I., Ko K., Kim E., Pickup S., Maislin G., et al. Altered upper airway and soft tissue structures in the New Zealand Obese mouse. Am J Respir Crit Care Med 2009, 179:158-169.
153. 2 reserve in sleeping dogs. J Appl Physiol 1985, 2007(103):1942-1949.
154. Kimoff R.J., Brooks D., Horner R.L., Kozar L.F., Render-Teixeira C.L., Champagne V., et al. Ventilatory and arousal responses to hypoxia and hypercapnia in a canine model of obstructive sleep apnea. Am J Respir Crit Care Med 1997, 156:886-894.
155. Launois S.H., Averill N., Abraham J.H., Kirby D.A., Weiss J.W. Cardiovascular responses to nonrespiratory and respiratory arousals in a porcine model. J Appl Physiol 1985, 2001(90):114-120.
156. White S.G., Fletcher E.C., Miller C.C. Acute systemic blood pressure elevation in obstructive and nonobstructive breath hold in primates. J Appl Physiol 1985, 1995(79):324-330.
157. Farre R., Rotger M., Montserrat J.M., Calero G., Navajas D. Collapsible upper airway segment to study the obstructive sleep apnea/hypopnea syndrome in rats. Respir Physiol Neurobiol 2003, 136:199-209.
158. Nacher M., Serrano-Mollar A., Farre R., Panes J., Segui J., Montserrat J.M. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol 2007, 155:93-96.
159. Schneider H., Schaub C.D., Chen C.A., Andreoni K.A., Schwartz A.r., Smith P.L., et al. Effects of arousal and sleep state on systemic and pulmonary hemodynamics in obstructive apnea. J Appl Physiol 1985, 2000(88):1084-1092.
160. Van Dongen H.P., Maislin G., Mullington J.M., Dinges D.F. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003, 26:117-126.
161. Farre R., Nacher M., Serrano-Mollar A., Galdiz J.B., Alvarez F.J., Navajas D., et al. Rat model of chronic recurrent airway obstructions to study the sleep apnea syndrome. Sleep 2007, 30:930-933.
162. Hamrahi H., Stephenson R., Mahamed S., Liao K.S., Horner R.L. Selected Contribution: Regulation of sleep-wake states in response to intermittent hypoxic stimuli applied only in sleep. J Appl Physiol 1985, 2001(90):2490-2501.
163. Bonsignore M.R., Marrone O., Insalaco G., Bonsignore G. The cardiovascular effects of obstructive sleep apnoeas: analysis of pathogenic mechanisms. Eur Respir J 1994, 7:786-805.
164. McGuire M., Bradford A. Chronic intermittent hypercapnic hypoxia increases pulmonary arterial pressure and haematocrit in rats. Eur Respir J 2001, 18:279-285.
165. Carley D.W., Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am J Respir Crit Care Med 1999, 160:1824-1829.
166. Trbovic S.M., Radulovacki M., Carley D.W. Protoveratrines A and B increase sleep apnea index in Sprague-Dawley rats. J Appl Physiol 1985, 1997(83):1602-1606.
167. Fletcher E.C. Invited review: Physiological consequences of intermittent hypoxia: systemic blood pressure. J Appl Physiol 1985, 2001(90):1600-1605.
168. Julien C., Bayat S., Levy P. Vascular reactivity to norepinephrine and acetylcholine after chronic intermittent hypoxia in mice. Respir Physiol Neurobiol 2003, 139:21-32.
169. Kanagy N.L., Walker B.R., Nelin L.D. Role of endothelin in intermittent hypoxia-induced hypertension. Hypertension 2001, 37:511-515.
170. Lesske J., Fletcher E.C., Bao G., Unger T. Hypertension caused by chronic intermittent hypoxia-influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997, 15:1593-1603.
171. McNulty P.H., Ng C., Liu W.X., Jagasia D., Letsou G.V., Baldwin J.C., et al. Autoregulation of myocardial glycogen concentration during intermittent hypoxia. Am J Physiol 1996, 271:R311-R319.
172. Polotsky V.Y., Li J., Punjabi N.M., Rubin A.E., Smith P.L., Schwartz A.R., et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 2003, 552:253-264.
173. Tahawi Z., Orolinova N., Joshua I.G., Bader M., Fletcher E.C. Altered vascular reactivity in arterioles of chronic intermittent hypoxic rats. J Appl Physiol (1985) 2001, 90:2007-2013. discussion 2000.
174. McGuire M., Bradford A. Chronic intermittent hypoxia increases haematocrit and causes right ventricular hypertrophy in the rat. Respir Physiol 1999, 117:53-58.
175. Perry J.C., D'Almeida V., Souza F.G., Schoorlemmer G.H., Colombari E., Tufik S. Consequences of subchronic and chronic exposure to intermittent hypoxia and sleep deprivation on cardiovascular risk factors in rats. Respir Physiol Neurobiol 2007, 156:250-258.